Issue 57, 2014

A hyaluronic acid–methotrexate conjugate for targeted therapy of rheumatoid arthritis

Abstract

In an effort to improve the therapeutic efficacy of methotrexate (MTX), we prepared the hyaluronic acid–MTX conjugate for targeted therapy of rheumatoid arthritis (RA). Owing to the pH-sensitive nature of the conjugate, MTX was rapidly released under the mildly acidic conditions, similar to the environment of inflamed synovial tissue in RA.

Graphical abstract: A hyaluronic acid–methotrexate conjugate for targeted therapy of rheumatoid arthritis

Supplementary files

Article information

Article type
Communication
Submitted
08 Apr 2014
Accepted
16 May 2014
First published
20 May 2014

Chem. Commun., 2014,50, 7632-7635

A hyaluronic acid–methotrexate conjugate for targeted therapy of rheumatoid arthritis

J. M. Shin, S. Kim, T. Thambi, D. G. You, J. Jeon, J. O. Lee, B. Y. Chung, D. Jo and J. H. Park, Chem. Commun., 2014, 50, 7632 DOI: 10.1039/C4CC02595D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements